Understanding stopping rules: what would prompt stopping the compound? Adverse effect, lack of benefit after a defined time, or other reasons? Knowing in advance is better than surprise discontinuation.
Second pass at: When your prescriber and the evidence disagree
What to bring: copies of relevant lab results, pharmacy records (to confirm doses actually taken), and records of any adverse effects you have experienced with other medications. Documentation is stronger than memory.
Prescription logistics: confirm whether it will be filled locally, requires mail order, or will be prescribed off-label and needs a compounding pharmacy. Different paths have different implications.
post #23 is right about the mechanism and I think understates the practical bit.
Clarifying indication: if a compound is approved for diabetes but you have obesity without diabetes, clarify whether your clinician considers this off-label use and what the evidence basis is.
Discussing side effects: be specific. "Nausea" is less useful than "I have nausea worst 24 to 36 hours after injection, severity 2 to 3 out of 4, stable over weeks". That description helps determine whether to adjust dose or dose timing.
Preparing for an appointment: bring recent bloodwork, a list of current medications with doses and timing, and any questions written out. Written questions get better answers than questions asked on the fly.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
post #52 answers the question as asked. The question underneath it is different.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
Read the full topic (56 posts)
This topic was referenced in
- When your prescriber and the evidence disagreeClinical › Prescriber conversations · 18 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
What to bring: records that a clinician can actually use — a second dataset
What to bring: records that a clinician can actually use — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about a population rather than…
|
+80 | 86 | 5.6k | 3h |
|
Coming back to: Preparing for an appointment: one page, three questions
Posting this under the heading it deserves: Preparing for an appointment: one page, three questions Everything below is what sits behind that. General question, not a request for advice about my own care — I…
|
+139 | 151 | 47k | 18mo |
|
Preparing for an appointment: one page, three questions
Posting this under the heading it deserves: Preparing for an appointment: one page, three questions Everything below is what sits behind that. General question, not a request for advice about my own care — I…
|
+28 | 32 | 57k | 11mo |
|
What a good consultation looks like from the other side
What a good consultation looks like from the other side — that is the question, and I have not found it answered plainly anywhere I have looked. Asking about a population rather than about a person. The…
|
+57 | 62 | 4.9k | 22h |
|
Coming back to: Getting a referral rather than a refusal
Posting this under the heading it deserves: Getting a referral rather than a refusal Everything below is what sits behind that. General question, not a request for advice about my own care — I know the…
|
+69 | 74 | 1.7k | 13mo |
Related topics — sharing the tags beginner friendly, type 2 diabetes, telehealth
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Molecular mass of semaglutide and why the figure differs between sources
Molecular mass of semaglutide and why the figure differs between sources — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…
|
+101 | 110 | 12k | 16h |
|
Step therapy requirements and how to satisfy them
Posting this under the heading it deserves: Step therapy requirements and how to satisfy them Everything below is what sits behind that. A coverage question with the paperwork detail included, since that is…
|
+21 | 25 | 49k | 2mo |
|
Reading a denial letter as a specification for your appeal
Reading a denial letter as a specification for your appeal Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that…
|
3 | 30k | 12mo | |
|
The anatomy of a question that gets answered within an hour — does this still hold?
The anatomy of a question that gets answered within an hour — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Question in the title. Context…
|
+19 | 23 | 40k | 14d |
|
Second pass at: Semaglutide and alcohol: what is actually documented
Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…
|
+15 | 19 | 4.4k | 13mo |